Search: (WFRF:(Hicks Rodney J)) srt2:(2015-2019)
> (2017) >
ENETS Consensus Gui...
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms : Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues
-
- Hicks, Rodney J. (author)
- Peter MacCallum Canc Ctr, Canc Imaging & Neuroendocrine Serv, 305 Grattan St
-
- Kwekkeboom, Dik J. (author)
- Erasmus MC, ENETS Ctr Excellence Rotterdam, Div Nucl Med, Dept Internal Med
-
- Krenning, Eric (author)
- Erasmus MC, Cyclotron Rotterdam BV
-
show more...
-
- Bodei, Lisa (author)
- Mem Sloan Kettering Canc Ctr
-
- Grozinsky-Glasberg, Simona (author)
- Hadassah Hebrew Univ, Med Ctr, Neuroendocrine Tumor Unit, Endocrinol & Metab Serv,Dept Med
-
- Arnold, Rudolf (author)
- Munich, Germany
-
- Borbath, Ivan (author)
- Clin Univ St Luc, Serv Gastroenterol
-
- Cwikla, Jaroslaw (author)
- Univ Warmia & Mazury, Dept Radiol, Fac Med Sci
-
- Toumpanakis, Christos (author)
- Royal Free Hosp, Neuroendocrine Tumour Unit
-
- Kaltsas, Greg (author)
- Natl Univ Athens, Div Endocrinol, Dept Pathophysiol
-
- Davies, Philippa (author)
- Royal Free Hosp, Neuroendocrine Tumour Unit
-
- Hoersch, Dieter (author)
- Gastroenterol & Endocrinol Ctr Neuroendocrine Tum
-
- Tiensuu Janson, Eva (author)
- Uppsala universitet,Onkologisk endokrinologi
-
- Ramage, John (author)
- Hampshire Hosp NHS Trust, Gastroenterol Dept, Basingstoke
-
show less...
-
(creator_code:org_t)
- 2017-04-13
- 2017
- English.
-
In: Neuroendocrinology. - : KARGER. - 0028-3835 .- 1423-0194. ; 105:3, s. 295-309
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish Lu-177-DOTA-octreotate (LutaThera (R)) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Endokrinologi och diabetes (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Endocrinology and Diabetes (hsv//eng)
Keyword
- Radiolabelled somatostatin analogues
- Gastroenteropancreatic neuroendocrine tumour
- Neuroendocrine tumour
- Peptide receptor radionuclide therapy
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Hicks, Rodney J.
-
Kwekkeboom, Dik ...
-
Krenning, Eric
-
Bodei, Lisa
-
Grozinsky-Glasbe ...
-
Arnold, Rudolf
-
show more...
-
Borbath, Ivan
-
Cwikla, Jaroslaw
-
Toumpanakis, Chr ...
-
Kaltsas, Greg
-
Davies, Philippa
-
Hoersch, Dieter
-
Tiensuu Janson, ...
-
Ramage, John
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Basic Medicine
-
and Neurosciences
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Endocrinology an ...
- Articles in the publication
-
Neuroendocrinolo ...
- By the university
-
Uppsala University